platinum has been researched along with Response Evaluation Criteria in Solid Tumors in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeddaim, C; Anota, A; Brocard, F; Cancel, M; Floquet, A; Frenel, JS; Hardy-Bessard, AC; Houlier, A; Kalbacher, E; Lardy-Cleaud, A; Largillier, R; Levaché, CB; Lortholary, A; Louvet, C; Meunier, J; Mouret-Reynier, MA; Pissaloux, D; Pop, O; Provansal, M; Ray-Coquard, I; Savoye, AM; Trédan, O; Treilleux, I; Venat-Bouvet, L; You, B; Zannetti, A | 1 |
| Kågedal, M; Wang, N; Yu, J | 1 |
| Fu, W; Goldberg, KB; Kim, G; Liu, Q; Maher, VE; Ning, YM; Palmby, T; Pazdur, R; Ricks, T; Suzman, D; Tang, S; Zhang, L | 1 |
| Ayhan, A; Burges, A; Creemers, GJ; Davies, L; Gebski, V; Hilpert, F; Huizing, M; Kristensen, G; Lee, CK; Lindemann, K; Lykka, M; Mirza, MR; Pujade-Lauraine, E; Raspagliesi, F; Romero, I; Rubio, MJ | 1 |
3 trial(s) available for platinum and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phenylurea Compounds; Platinum; Pyridines; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Treatment Outcome | 2022 |
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics.
Topics: Biomarkers, Tumor; CA-125 Antigen; Decision Making; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Membrane Proteins; Models, Theoretical; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Predictive Value of Tests; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sodium-Phosphate Cotransporter Proteins, Type IIb; Software; Topoisomerase II Inhibitors; Treatment Outcome; Tumor Burden | 2020 |
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Response Evaluation Criteria in Solid Tumors | 2016 |
1 other study(ies) available for platinum and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Drug Approval; Female; Humans; Male; Middle Aged; Platinum; Response Evaluation Criteria in Solid Tumors; Risk Assessment; Treatment Outcome; United States; United States Food and Drug Administration; Urologic Neoplasms; Urothelium | 2017 |